By Business/Source
Currency:USD
2025/Q2
Stock NameRevenueRatio
Commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening400K100.00%
By Country/Region
Currency:USD
2023/FY
Stock NameRevenueRatio
United States3.5M100.00%